PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT05049837
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Group Specific Aim 1 — OTHER
    600 cases: two normal and two tumor formalin-fixed tissue samples
  • Group Specific Aim 2 — OTHER
    600 cases: two normal and two tumor formalin-fixed tissue samples.
  • Group Specific Aim 3 — OTHER
    600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples
  • Group Specific Aim 4 — OTHER
    600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
  • Group Specific Aim 5 — OTHER
    600 cases; two normal and two tumor formalin-fixed tissue samples
  • Group Specific Aim 6 — OTHER
    210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.

Study Details

In this Project, we will use therapeutic target -focused (TTF) profiling, genome-wide mRNA profiling and assessments of tumor phosphopeptides and DNA that are shed into the blood stream to define how various molecular factors alone and in combination relate to resistance to therapy, to prognosis, and to metastatic patterns at relapse. We will examine how the presence of factors that drive cell growth, antagonize apoptosis, or confer resistance in other ways may counter the effect of systemic therapies and/or promote rapid tumor recurrence. In this way, we will identify new, previously unappreciated potential therapeutic targets while also identifying which targets are most likely to increase resistance to therapy and worsen prognosis.

Key Dates

Start date
Apr 25, 2007
Status verified
Aug 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
7,200 participants (estimated)

Arms

  • Arm: Specific Aim 1
    600 cases: two normal and two tumor formalin-fixed tissue samples
  • Arm: Specific Aim 2
    600 cases: two normal and two tumor formalin-fixed tissue samples.
  • Arm: Specific Aim 3
    600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples.
  • Arm: Specific Aim 4
    600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
  • Arm: Specific Aim 5
    600 cases; two normal and two tumor formalin-fixed tissue samples
  • Arm: Specific Aim 6
    210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.

Primary Outcome Measure

To develop a therapeutic target -focused (TTF) profiling platform and to use it in vitro to identify potential therapeutic targets associated with therapeutic resistance and to develop novel approaches against these potential targets. [ Time Frame: through study completion, an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
M D Anderson Caner CenterHoustonTexas77030
Luisa M Solis Soto, MD
[email protected]
832-794-1469

Find similar trials in Houston, TX

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
M D Anderson Caner Center· Houston, TX

Related Studies